Habermann: Exosomes have potential for Dx, many isolation methods (ultracentrifgure, exoquick) #MDxEU17
12:14pm April 11th 2017 via Hootsuite
Habermann: cfDNA fragmentation, difference in amount, isolation methods. No std handlling, or preanalytical handling #MDxEU17
12:13pm April 11th 2017 via Hootsuite
Habermann: #MDxEU17 REMARK ref from '06 https://t.co/sC8lT9dWDF Onto cfDNA: several sources, structural forms (exosomes etc)
12:12pm April 11th 2017 via Hootsuite
Habermann: Want to dev a CTC-Guide, 3 different guidelines (REMARK, '05, STARD, '03, CONSORT) 2.2 preanalytical conditions #MDxEU17
12:11pm April 11th 2017 via Hootsuite
Habermann: Concl: high diversity in terms of processing, storage and reporting, but still high value as prognostic markers #MDxEU17
12:09pm April 11th 2017 via Hootsuite
Habermann: Reviewed all the variability in blood quality management - 37% EDTA, 73% peripheral, 27% central #MDxEU17
Habermann: 17 different markers for qRT-PCR method alone. 40% didn't use controls. One study n=735 no controls #MDxEU17
12:08pm April 11th 2017 via Hootsuite
Habermann: The challenge of tumor heterogeneity, as well as the reprod of marker data. Lit review for 71 studies of CTCs in CRC #MDxEU17
12:07pm April 11th 2017 via Hootsuite
Jens Habermann (Univ Lubeck GE) Standardization of liquid biopsies for prec med in oncology: a task for clinical biobanks? #MDxEU17
12:04pm April 11th 2017 via Hootsuite
Q: Interlab lower limit? Devonshire: Methods are down to 0.1% #MDxEU17
12:03pm April 11th 2017 via Hootsuite
DevonshireL Credits include Adam Corner of @RainDanceTech , and Patricia Hegerich at @thermofisher #MDxEU17
11:59am April 11th 2017 via Hootsuite
Devonshire: Raises the point, perhaps a ref std from their reference lab would cut across groups, instead of linearly (orig diag) #MDxEU17
11:58am April 11th 2017 via Hootsuite
Devonshire: Issues were at the software analysis stage. Details in this '17 ref https://t.co/cx1WH7dV32 #MDxEU17
11:53am April 11th 2017 via Hootsuite
Devonshire: Looking across 21 labs all using QX200, without calibration good agreement of WT. For KRAS, found 3 outlier labs #MDxEU17
11:52am April 11th 2017 via Hootsuite
Devonshire: Showed agreement between QX200, RDT, QS3D, BioMark, Constellation. (Constellation was highest though.) #MDxEU17
11:49am April 11th 2017 via Hootsuite
Devonshire: Showed good agreement. Showed Scorpion having higher copy number at low conc (false pos). #MDxEU17
Devonshire: Dev KRAS G12D plasmids, 100 copies/rcn, also 1K copies/rcn. 5 assays (hydrolysis probe, scorpion, intercalating dyes) #MDxEU17
11:48am April 11th 2017 via Hootsuite
Devonshire: Looking at KRAS, two main factors causing bias - assay chemistry, and dPCR platform/technology #MDxEU17
11:46am April 11th 2017 via Hootsuite
Devonshire: Use flow cytometry, dPCR, CE and other methods showing good agreement w/o external calibration https://t.co/h97XkG0paY #MDxEU17
11:45am April 11th 2017 via Hootsuite
Devonshire: an example of US NIST with Std RM 2366 for CMV https://t.co/Xu0X75yUSn #MDxEU17
11:43am April 11th 2017 via Hootsuite
Devonshire: No ext calibration; high precision, high sensitivity, suitable for complex matrices #MDxEU17
11:42am April 11th 2017 via Hootsuite
Devonshire: Points out that LDTs are only at the bottom level, not back to mfr, nor ref lab. dPCR as a potential ref method #MDxEU17
11:41am April 11th 2017 via Hootsuite
Devonshire: From ref lab to Dx mfr, to testing lab. Qty traceable to an SI unit at the top. LGC is at the top (ref lab), primary #MDxEU17
11:39am April 11th 2017 via Hootsuite
Devonshire: ISO 17511 - in vitro dx tests giving traceable values. Shows flow diagram - primary calibrator, mfr's calibrator etc #MDxEU17
11:38am April 11th 2017 via Hootsuite
Devonshire: Qual: LOD; Quant: fold change, copies/mL, %MAF. Cp methods, over time, between labs. #MDxEU17
11:36am April 11th 2017 via Hootsuite
Devonshire #MDxEU17 Fig from this '17 review https://t.co/XZRfDsH3ql KRAS as model - 40% of many solid tumors. '17 https://t.co/tdKgq4SpGg
11:35am April 11th 2017 via Hootsuite
Devonshire: COLD-PCR, qPCR, dPCR, amplicon, WES, WGS. Outputs can be +/-, can be absolute, or could be relative mutant/WT #MDxEU17
11:33am April 11th 2017 via Hootsuite
Alison Devonshire (LCG UK): Role of dPCR in supporting the standarization of liquid biopsy measurements #MDxEU17
11:32am April 11th 2017 via Hootsuite
Q: Given limited amount of cells, how to examine mutations? Rossi: Use digital PCR, #MDxEU17
10:31am April 11th 2017 via Hootsuite
Rossi: Persistence of viable CTCs in the bloodstream should be considered a sign of aggressive disease. #MDxEU17
10:29am April 11th 2017 via Hootsuite
Rossi: 2nd case, EGFR-inh. CTCs were EpCAM+, looked for EGFRinh in cfDNA and tissue. Found L858R in cfDNA, not in tumor until 5mo #MDxEU17
10:28am April 11th 2017 via Hootsuite
Rossi: For 1 case, EML4-ALK+, Crizotinib treatment, CTCs increased as pt progressed '16 ref https://t.co/D5VPCNITOv #MDxEU17
10:25am April 11th 2017 via Hootsuite
Rossi: Able to pick up EML4-ALK in CTCs, used M30 as an apoptotic marker. #MDxEU17
10:22am April 11th 2017 via Hootsuite
Rossi: Cytokeratin analyses; K-M curves show clear diff in risk; (have two assays, a Std Assay, and an Expanded Assay) #MDxEU17
10:20am April 11th 2017 via Hootsuite
Rossi: 2 blood draws. Measured CTC+ pts, and total CTC numbers. 52% present '1 or more CTCs'. ID'd apoptotic CTCs and excluded #MDxEU17
10:18am April 11th 2017 via Hootsuite
Rossi: Looking at mBC, mCRC and mPC overall survival. n=189 with adv NSCLC, 12 mo follow-up. First-line trtmt. #MDxEU17
10:16am April 11th 2017 via Hootsuite
Elisabetta Rossi (Univ Padova Italy) Could CTCs monitoring and characterization reflect response to treatment in NSCLC? #MDxEU17
10:13am April 11th 2017 via Hootsuite
Q: How low can you detect? Vandenberghe: Unknown, due to low-pass NGS and unknown amount of tumor/normal cellularity in smpl #MDxEU17
Vandenberghe: Lueven is the birthplace of Anheuser-Busch. Shows a photo of a student reading a book 'and beer pouring in his head' #MDxEU17
10:10am April 11th 2017 via Hootsuite
Vandenberghe: Post-Rx, GR profile changes at only day 15. 9p24 is of great interest, as it is the location of PD-1 and PD-L1 #MDxEU17
10:06am April 11th 2017 via Hootsuite
Vandenberghe: Showed 10 samples 2p, 7q, 9p/9pter, where 24 concordant, 3 discordant (also from '15 ref) #MDxEU17
10:01am April 11th 2017 via Hootsuite
Vandenberghe: Prospectively, wanted to see if they could see similar amplifications in add'l 10 pts w/Hodgkins #MDxEU17
10:00am April 11th 2017 via Hootsuite
Vandenberghe: 27y/o with many abnormalities (MPSS), found HL. Fig from '15 ref https://t.co/mWRI2J9Xa0 Regions via FISH ampl. #MDxEU17
9:57am April 11th 2017 via Hootsuite
Vandenberghe: (The Hodgkin/Reed-Sterberg cell). Took blood, low-pass sequencing. #MDxEU17
9:55am April 11th 2017 via Hootsuite
Vandenberghe:Large therapeutic success, in the absence of a lot of understanding of the biology. Inflammatory stroma. 0.1-1% cells #MDxEU17
9:53am April 11th 2017 via Hootsuite
Vandenberghe: Largely curable, used to be fatal. But need de-escalative therapies due to treatment toxicities. #MDxEU17
9:52am April 11th 2017 via Hootsuite
Vandenberghe: #MDxEU17 Work recently published in '15 https://t.co/JwkzisXlBG Shows a H/R-S malignant cell. About 3/100,000 person-years.
9:51am April 11th 2017 via Hootsuite
Vandenberghe: Heme community has been much slower, since heme first appear in bone marrow. #MDxEU17
9:50am April 11th 2017 via Hootsuite
Peter Vandenberghe (UZ Leuven Belgium) cfDNA: a novel gateway to the genome of Reed-Sternberg cells in Hodgkin's Lymphoma? #MDxEU17
9:49am April 11th 2017 via Hootsuite
Warton: Credits volunteer blood donors. #MDxEU17
9:45am April 11th 2017 via Hootsuite
